Proteus Digital Health, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Proteus Digital Health, Inc.
Deal Snapshot: The firms are partnering on a digital therapeutic for schizophrenia in a deal potentially worth $500m.
Japanese pharmaceutical company picks up struggling US venture for a fraction of its one-time value as it continues strategic push into the digital health space.
Japanese firm picks up struggling US venture for a fraction of its one-time value as it continues strategic push into the digital health space.
Analysts are waiting to see how the drugs giant intends to drive growth for new products, with a particular interest in the prospects for the PARP inhibitor Zejula and the single-pill, two-drug HIV therapy Dovato.
- Digital Health
- Drug Delivery
- Monitoring Equipment & Devices
In Vitro Diagnostics
- Nanotechnology, Chips, etc.
- Other Names / Subsidiaries
- Proteus Biomedical Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.